Trial Profile
Use Of Intravitreal Aflibercept Injections In The Treatment Of Adult-Onset Vitelliform Detachments Associated With Pattern Dystrophy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Hereditary corneal dystrophies
- Focus Adverse reactions
- Acronyms AVA
- 30 Dec 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 29 Oct 2013 New trial record